Read by QxMD icon Read

Heparin 7500

Mishna Joy, Eileen Tharp, Heather Hartman, Sara Schepcoff, Jennifer Cortes, Adam Sieg, Mark Mariski, Yeunju Lee, Meghan Murphy, Ghazaleh Ranjbar, Sherouk Sharaf, Gin Yau, Huimahn Alex Choi, Sophie Samuel
STUDY OBJECTIVE: To determine the safety and efficacy of high-dose subcutaneous unfractionated heparin (UFH) for prevention of venous thromboembolism (VTE) in overweight and obese patients. DESIGN: Single-center retrospective observational cohort study. SETTING: Large academic tertiary care medical center. PATIENTS: A total of 1335 adults who weighed more than 100 kg on admission and received either subcutaneous UFH 7500 units every 8 hours (751 patients [high-dose group]) or 5000 units every 8 hours (584 patients [low-dose group]) for VTE prophylaxis during their hospitalization between January 1, 2013, and August 31, 2014...
July 2016: Pharmacotherapy
Jeremy W Vandiver, Leticia I Ritz, Jeffrey T Lalama
Pharmacologic prophylaxis of deep vein thrombosis and venous thromboembolism (VTE) is an important aspect of medical care, particularly in the inpatient setting. Low-molecular weight heparins, heparin, and fondaparinux are commonly used agents to prevent VTE, each of which has well established dosing regimens in patients with normal body mass index. Dosing of these medications in morbidly obese populations (BMI > 40 kg/m(2)) is not as clearly defined in guidelines. This article reviews published data to support specific dosing regimens and monitoring strategies of these agents in this population...
April 2016: Journal of Thrombosis and Thrombolysis
Sophie Samuel, Emitseilu K Iluonakhamhe, Eileen Adair, Natalie Macdonald, Kiwon Lee, Teresa A Allison, Huimahn A Choi
Timing and dosing of chemical venous thromboembolism (VTE) prophylaxis in brain injury is controversial. Risk of bleeding while using high dose unfractionated heparin (UFH) in overweight patients to prevent VTE is also unknown. The purpose of this study was to describe the use of subcutaneous heparin 7500 units for VTE prophylaxis in overweight patients. This was a retrospective study comparing patients over 100 kg who received either 7500 units Q8 h (n = 141) (high dose group, HDG), or 5000 units Q8 h (n = 257) (traditional dose group, TDG), of UFH subcutaneously...
October 2015: Journal of Thrombosis and Thrombolysis
R D'Souza, S Keating, M Walker, S Drewlo, J Kingdom
INTRODUCTION: Heparin is often prescribed during pregnancy with the intention of improving perinatal outcomes on the basis that it exerts an anticoagulant action in the inter-villous space. Accumulating in-vitro and in-vivo evidence indicates that heparin's beneficial effects in pregnancy may result from 'non-anticoagulant' effects including the promotion of angiogenesis. METHODS: To study the effect of heparin within the placenta, we performed secondary analyses on a pilot trial where 32 women with negative thrombophilia screens and second-trimester evidence of placental insufficiency were randomized to standard care or antenatal self-administration of unfractionated heparin (UFH) 7500 IU twice-daily...
October 2014: Placenta
Joanne L Peterson, Eric D Phelps, Mark A Doll, Shlomit Schaal, Brian P Ceresa
PURPOSE: To provide a comprehensive study of the biological role and therapeutic potential of six endogenous epidermal growth factor receptor (EGFR) ligands in corneal epithelial homeostasis. METHODS: Kinetic analysis and dose response curves were performed by using in vitro and in vivo wound-healing assays. Biochemical assays were used to determine receptor expression and activity. Human tears were collected and quantitatively analyzed by multianalyte profiling for endogenous EGFR ligands...
May 2014: Investigative Ophthalmology & Visual Science
Sunila Tashfeen, Suhaib Ahmed, Farhat Abbas Bhatti, Nadir Ali
OBJECTIVE: To compare the sensitivity and specificity of Real Time Polymerase Chain Reaction (RT-PCR) with conventional cytogenetics in diagnosis of chronic myeloid leukemia. STUDY DESIGN: A cross-sectional, analytical study. PLACE AND DURATION OF STUDY: The Armed Forces Institute of Pathology (AFIP), Rawalpindi, from December 2010 to January 2012. METHODOLOGY: A total number of 40 patients were studied, in which all were diagnosed as CML on peripheral blood and bone marrow aspiration...
March 2014: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
Russell H Samson, Jennifer L Cline, David P Showalter, Michael R Lepore, Deepak G Nair
OBJECTIVE: Although controversial, carotid artery stenting (CAS) has been proposed as being safer than carotid endarterectomy (CEA) for patients with a contralateral internal carotid occlusion (CCO). Arguably, with a CCO, CAS should be even safer than CEA if a shunt is not used. Accordingly, we reviewed our experience with 2183 CEAs performed routinely without a shunt to evaluate the risk of CEA performed in a subset of 147 patients with a CCO. METHODS: Between 1988 and 2011, 147 CEAs (111 men [75%], 36 women [25%]) were routinely performed without a shunt despite CCO...
October 2013: Journal of Vascular Surgery
Pratap Kumar, Sameer Farouk Sait, Alok Sharma, Mukesh Kumar
Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of assisted reproduction technology. The syndrome is characterized by cystic enlargement of the ovaries and a fluid shift from the intravascular to the third space due to increased capillary permeability and ovarian neoangiogenesis. Its occurrence is dependent on the administration of human chorionic gonadotrophin (hCG). β-hCG and its analogs, estrogen, estradiol, prolactin, histamine and prostaglandins have all been implicated in OHSS but now it is increasingly better understood that the vasoactivesubstances such as interleukins, tumor necrosis factor-α, endothelin-1, and vascular endothelial growth factor (VEGF) secreted by the ovaries have been implicated in increasing vascular permeability...
May 2011: Journal of Human Reproductive Sciences
J C P Kingdom, M Walker, L K Proctor, S Keating, P S Shah, A McLeod, J Keunen, R C Windrim, J M Dodd
OBJECTIVE: To conduct a pilot randomized controlled trial of unfractionated heparin (UFH) in women considered at high risk of placental insufficiency in the second trimester. METHODS: Women with either false-positive first trimester (pregnancy-associated placental protein-A [PAPP-A] < 0.35 MoM) or second trimester (alpha-fetoprotein [AFP] > 2.0 MoM, inhibin > 3.0 MoM, human chorionic gonadotropin > 4.0 MoM) serum screening tests or medical/obstetric risk factors were screened for placental insufficiency by sonographic evaluation of the placenta and uterine artery Doppler between 18 and 22 weeks...
August 2011: Journal of Thrombosis and Haemostasis: JTH
H Boyce, H Hume-Smith, J Ng, M O Columb, G M Stocks
BACKGROUND: Thromboprophylaxis is commonly required following caesarean section. However the effect of thromboprophylactic dosages of subcutaneous heparin on coagulation is unknown because conventional laboratory tests are largely unaffected. The aim of this study was to determine if thromboelastography could detect and quantify the effect of unfractionated heparin on coagulation profile when given at the time of surgery. METHODS: Nineteen women undergoing elective caesarean section were recruited...
July 2011: International Journal of Obstetric Anesthesia
Carlos F Sánchez-Ferrer
Bemiparin is a low molecular weight heparin (LMWH) that has been available in Europe for 10 years and is indicated for thromboprophylaxis and the treatment of deep vein thrombosis. Bemiparin is termed a 'second-generation' LMWH, because at 3.6 kDa, it has a lower mean molecular weight than other LMWH and a narrow distribution of saccharide chain lengths, with most being less than 6 kDa. As a result of its low molecular weight, it has low anti-factor IIa (thrombin) activity and an anti-Xa : anti-IIa activity ratio of 8 : 1 compared with a ratio of 1 : 1 for unfractionated heparin...
December 14, 2010: Drugs
Sebastian M Schellong, Sylvia Haas, Andreas Greinacher, Uta Schwanebeck, Christian Sieder, Claudia Abletshauser, Peter Bramlage, Hanno Riess
OBJECTIVE: Guidelines recommend low-dose unfractionated heparin (UFH) and low-molecular-weight heparin for the prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients. We report the findings of an open-label, active-controlled, multicenter study in acutely ill medical patients comparing certoparin and UFH. RESEARCH DESIGN AND METHODS: Open-label, active-controlled, multicenter study. Patients received certoparin 3000 IU daily or UFH 7500 IU twice daily...
December 2010: Expert Opinion on Pharmacotherapy
H N Magnani
UNLABELLED: Danaparoid case reports of 91 pregnancies in 83 patients with a history of thrombophilia and/or intra-uterine growth retardation have been analysed. All had intolerance to the heparins including HIT and acute or past thromboses or a history of repeated pregnancy loss (RPL). Danaparoid was started in the first, second and third trimesters in 60.2%, 19.3% and 20.5% pregnancies respectively at a dosing intensity of 1000 to 7500 U/day. Subcutaneous and/or intravenous administration was continued for a median 105 days (range 1-252) during pregnancy and 7 days (range 2 to 56) post-partum...
April 2010: Thrombosis Research
M V Pavlova, N E Fedorova, A V Serbin, E V Klimova, E N Karaseva, S A Golyshev, A A Kushch
Human cytomegalovirus (CMV), an agent of infection (CMVI), lethally dangerous for immune deficient neonates and adults was investigated in vitro as a target for a therapeutic effect of new membrane-active polyanionic compounds (MPC). Previous studies on the alicycle- and sulfate-modified carboxy-MPCs revealed a well-defined tendency of the anti-CMV activity amplification in parallel with increasing of the content of sulfate groups, enhancing the negative charge of the macromolecule. The dominating role of the electrostatic factor was confirmed by the highest activity of AS-688, compound with maximum sulfation among the tested MPCs...
2008: Antibiotiki i Khimioterapii︠a︡, Antibiotics and Chemoterapy [sic]
Ervin Zuljević, Gzim Redzepi, Sanja Plestina, Vinko Vidjak, Vlasta Loncarić, Marko Jakopović, Miroslav Samarzija
38-year-old man had chronic deep venous thrombosis (DVT) as a result of multiple injuries caused by an explosion of grenade 12 years ago, with recurrent pulmonary thromboembolisms and pulmonary hypertension which was unrecognized for a decade. Patient was admitted with a progressive dyspnea and exercise intolerance (NYHA II). The diagnosis was established according to clinical symptoms, transthoracic echocardiography, phlebography, lung scintigraphy and pulmonary angiography. Oral anticoagulant therapy was introduced and cava filter indicated to implant...
March 2009: Collegium Antropologicum
Jonas Oldgren, Nina Johnston, Agneta Siegbahn
BACKGROUND: We evaluated coagulation activity in relation to gender in patients with acute coronary syndromes and in healthy individuals of similar age, and related coagulation activity to levels of Xa inhibition during dalteparin treatment. METHODS: Serial blood samples were obtained from 555 (172 women) of 2267 patients in the Scandinavian FRISC II study, and a single sample in 457 (151 women) apparently healthy age- and sex-matched individuals. After randomization, all patients received dalteparin 120 IU/kg s...
March 2008: American Heart Journal
Enoch Akowuah, Andreas Baumbach, Peter Wilde, Gianni Angelini, Alan J Bryan
OBJECTIVE: Our objective was to compare early results of endovascular stenting for traumatic aortic rupture with conventional open repair. METHODS: We conducted a retrospective review of consecutive cases of traumatic aortic rupture in a single institution from July 2000 to July 2006. RESULTS: Fifteen cases were identified. The mean injury severity score was 43 +/- 10. Fourteen patients had the procedure within 24 hours of admission to the hospital...
October 2007: Journal of Thoracic and Cardiovascular Surgery
Christopher Zappala, Snehal Chandan, Narelle George, Joan Faoagali, Robert J Boots
AIM: The mucolytic, anticoagulative, anti-inflammatory and neo-angiogenic properties of inhaled heparin may benefit patients with burns and cystic fibrosis. We assessed the antibacterial effects of unfractionated heparin. METHODS: Stored clinical isolates of Acinetobacter baumannii (n =4), Candida albicans (n = 5), Haemophilus influenzae (n =5), Klebsiella pneumoniae (n =4), methicillin-resistant Staphylococcus aureus (n=3), Pseudomonas aeruginosa (n = 2), and Streptococcus pneumoniae (n = 7) were subcultured on horse blood agar, incubated at 35 degrees C overnight, then inoculated into trypticase soy broth to a density of 1 McFarland standard...
June 2007: Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine
Edelgard Lindhoff-Last, Hans-Joachim Kreutzenbeck, Harry N Magnani
Pregnant patients with acute venous thrombosis or a history of thrombosis may need alternative anticoagulation, when heparin intolerance occurs. Only limited data on the use of the heparinoid danaparoid are available in literature. We reviewed the use of danaparoid in 51 pregnancies of 49 patients identified in literature between 1981 and 2004. All patients had developed heparin intolerance (32 due to heparin-induced thrombocytopenia, 19 mainly due to heparin-induced skin rashes) and had a current and/or past history of thromboembolic complications...
January 2005: Thrombosis and Haemostasis
Mary H H Ensom, Mary D Stephenson
OBJECTIVE: Little pharmacokinetic data are available for either low molecular weight heparins (LMWHs) or unfractionated heparins (UFHs) in pregnancy. The objectives of this study were to determine whether differences exist in the pharmacokinetics of dalteparin and UFH before and during the first, second, and third trimesters of pregnancy in women with the antiphospholipid antibody syndrome (APS). Adjustments in our dosing protocol would be made if differences existed. METHODS: Women with APS who were contemplating pregnancy were randomized to dalteparin 2500 U, 2500 U, 5000 U, and 7500 U daily, or UFH 5000 U, 5000 U, 7500 U, and 10,000 U every 12 hours, prior to pregnancy and the first, second, and third trimesters, respectively...
September 2004: Journal of the Society for Gynecologic Investigation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"